Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated:  1/5/2017
Pfizer Investigational Site
mi
from
Winston-Salem, NC
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated: 1/5/2017
Pfizer Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated:  1/5/2017
Pfizer Investigational Site
mi
from
Greer, SC
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated: 1/5/2017
Pfizer Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated:  1/5/2017
Pfizer Investigational Site
mi
from
St John's,
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis
Status: Enrolling
Updated: 1/5/2017
Pfizer Investigational Site
mi
from
St John's,
Click here to add this to my saved trials
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated:  1/10/2017
National Jewish Health
mi
from
Denver, CO
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated:  1/10/2017
Children's Hospital Boston
mi
from
Boston, MA
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)
Status: Enrolling
Updated: 1/10/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated:  1/10/2017
University of California, San Diego
mi
from
San Diego, CA
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated:  1/10/2017
National Jewish Health
mi
from
Denver, CO
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis
Status: Enrolling
Updated: 1/10/2017
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Status: Enrolling
Updated:  1/10/2017
National Jewish Health
mi
from
Denver, CO
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route
Status: Enrolling
Updated: 1/10/2017
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195
Status: Enrolling
Updated:  1/23/2017
Parexel Baltimore Early Phase Clinical Unit
mi
from
Baltimore, MD
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195
Status: Enrolling
Updated: 1/23/2017
Parexel Baltimore Early Phase Clinical Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
UC San Diego
mi
from
La Jolla, CA
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
UC San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Justus J. Fiechtner, MD, PC
mi
from
Lansing, MI
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Justus J. Fiechtner, MD, PC
mi
from
Lansing, MI
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Metroplex Clinical Research Center
mi
from
Dallas, TX
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Metroplex Clinical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Seattle Rheumatology Associates/Swedish Clinical Research
mi
from
Seattle, WA
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Seattle Rheumatology Associates/Swedish Clinical Research
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Stanford University
mi
from
Palo Alto, CA
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated:  1/23/2017
Northwestern University
mi
from
Chicago, IL
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status: Enrolling
Updated: 1/23/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
S. Aureus Colonization in Atopic Dermatitis
Staphylococcus Aureus Colonization in Atopic Dermatitis
Status: Enrolling
Updated:  1/31/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
S. Aureus Colonization in Atopic Dermatitis
Staphylococcus Aureus Colonization in Atopic Dermatitis
Status: Enrolling
Updated: 1/31/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Birmingham, AL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Long Beach, CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Mission Viejo, CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
San Diego (3 locations), CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
San Diego (3 locations), CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Denver, CO
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Tampa (2 locations), FL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Tampa (2 locations), FL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Macon, GA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Chicago, IL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Maywood, IL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
West Dundee, IL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
West Dundee, IL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Overland Park, KA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Boston, MA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Troy, MI
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
St. Louis, MO
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Albuquerque (2 locations), NM
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Albuquerque (2 locations), NM
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
mi
from
Miami (2 locations), FL
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
mi
from
Miami (2 locations), FL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Plainfield, IN
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Plainfield, IN
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Buffalo, NY
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Forest Hills, NY
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Forest Hills, NY
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
New York, NY
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Cleveland, OH
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Norman, OK
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Norman, OK
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Tulsa, OK
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Medford, OR
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
mi
from
Portland (2 locations), OR
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
mi
from
Portland (2 locations), OR
Click here to add this to my saved trials